Regeneron Pharmaceuticals, Inc.
0R2M.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$80.67B
Close$
Share Statistics
| Market cap | $80.67 Billion |
|---|---|
| Enterprise Value | $80.67 Billion |
| Dividend Yield | $3.70 (0.50%) |
| Earnings per Share | $43.07 |
| Beta | 0.25 |
| Outstanding Shares | 102,800,000 |
Return
| Return on Equity | 13650468.29% |
|---|---|
| Return on Assets | 10373112.87% |
| Return on Invested Capital | 12363812.15% |
Valuation & Multiples
| P/E Ratio | 17.83 |
|---|---|
| PEG | -261.95 |
| Price to Sales | 4.95 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.19 |
| Enterprise Value to EBIT | 18.02 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$10.16
Average shareholder expectationRevenue Estimate
$3.82 B
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
$16.03
Average shareholder expectationRevenue Estimate
$4.54 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Regeneron Pharmaceuticals, Inc.
15,410 employees
CEO: Leonard Schleifer Regeneron Pharmaceuticals, Inc. functions as a global biopharmaceutical enterprise, concentrating its efforts on the research, creation, advancement, production, and global commercialization of medicinal treatments for a diverse array of...